生物制药

Biopharmaceuticals are revolutionizing the treatment of chronic diseases like cancer and diabetes.
生物制药正在彻底改变癌症和糖尿病等慢性疾病治疗领域。
The development of novel biopharmaceuticals often involves complex genetic engineering techniques.
新型生物制药的研发通常涉及复杂的基因工程技术。
Insulin, a key biopharmaceutical, is derived from genetically modified organisms (GMOs).
胰岛素，一种关键的生物药物，来源于转基因生物（GMOs）。
Biopharmaceutical companies are investing heavily in research and clinical trials for new therapies.
生物制药企业正大力投资于新疗法的研究和临床试验。
Monoclonal antibodies, a type of biopharmaceutical, have shown exceptional effectiveness in treating autoimmune disorders.
单克隆抗体，一种生物制药，对自身免疫性疾病表现出卓越的疗效。
The regulatory approval process for biopharmaceuticals can be lengthy and rigorous.
生物制药的审批流程可能既漫长又严格。
Biopharmaceuticals are often more expensive than traditional pharmaceuticals due to their complex manufacturing processes.
由于复杂的生产过程，生物制药通常比传统药品价格更高。
Personalized biopharmaceuticals, tailored to individual patients' genetic profiles, are an emerging trend.
针对个体患者基因特征定制的个性化生物制药是新兴趋势。
Biopharmaceuticals play a crucial role in improving patient outcomes and extending life expectancy.
生物制药在提升患者生活质量、延长寿命方面发挥着关键作用。
In recent years, there has been a surge in collaborations between academia and industry in biopharmaceutical research.
近年来，学术界与产业界在生物制药研究方面的合作日益增多。